Show simple item record

dc.contributor.authorSullivan, Michael K
dc.contributor.authorLees, Jennifer S
dc.contributor.authorDrake, Thomas M
dc.contributor.authorDocherty, Annemarie B
dc.contributor.authorOates, Georgia
dc.contributor.authorHardwick, Hayley E
dc.contributor.authorRussell, Clark D
dc.contributor.authorMerson, Laura
dc.contributor.authorDunning, Jake
dc.contributor.authorNguyen-Van-Tam, Jonathan S
dc.contributor.authorOpenshaw, Peter
dc.contributor.authorHarrison, Ewen M
dc.contributor.authorBaillie, J Kenneth
dc.contributor.authorISARIC4C Investigators
dc.contributor.authorSemple, Malcolm G
dc.contributor.authorHo, Antonia
dc.contributor.authorMark, Patrick B
dc.date.accessioned2022-04-28T23:30:49Z
dc.date.available2022-04-28T23:30:49Z
dc.date.issued2022-01-25
dc.identifier.issn0931-0509
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/336591
dc.description.abstractBACKGROUND: Acute kidney injury (AKI) is common in coronavirus disease 2019 (COVID-19). This study investigated adults hospitalized with COVID-19 and hypothesized that risk factors for AKI would include comorbidities and non-White race. METHODS: A prospective multicentre cohort study was performed using patients admitted to 254 UK hospitals with COVID-19 between 17 January 2020 and 5 December 2020. RESULTS: Of 85 687 patients, 2198 (2.6%) received acute kidney replacement therapy (KRT). Of 41 294 patients with biochemistry data, 13 000 (31.5%) had biochemical AKI: 8562 stage 1 (65.9%), 2609 stage 2 (20.1%) and 1829 stage 3 (14.1%). The main risk factors for KRT were chronic kidney disease (CKD) [adjusted odds ratio (aOR) 3.41: 95% confidence interval 3.06-3.81], male sex (aOR 2.43: 2.18-2.71) and Black race (aOR 2.17: 1.79-2.63). The main risk factors for biochemical AKI were admission respiratory rate >30 breaths per minute (aOR 1.68: 1.56-1.81), CKD (aOR 1.66: 1.57-1.76) and Black race (aOR 1.44: 1.28-1.61). There was a gradated rise in the risk of 28-day mortality by increasing severity of AKI: stage 1 aOR 1.58 (1.49-1.67), stage 2 aOR 2.41 (2.20-2.64), stage 3 aOR 3.50 (3.14-3.91) and KRT aOR 3.06 (2.75-3.39). AKI rates peaked in April 2020 and the subsequent fall in rates could not be explained by the use of dexamethasone or remdesivir. CONCLUSIONS: AKI is common in adults hospitalized with COVID-19 and it is associated with a heightened risk of mortality. Although the rates of AKI have fallen from the early months of the pandemic, high-risk patients should have their kidney function and fluid status monitored closely.
dc.format.mediumPrint
dc.publisherOxford University Press (OUP)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectacute kidney injury
dc.subjectdialysis
dc.subjectrenal failure
dc.subjectAcute Kidney Injury
dc.subjectCOVID-19
dc.subjectCohort Studies
dc.subjectHospital Mortality
dc.subjectHumans
dc.subjectMale
dc.subjectProspective Studies
dc.subjectRetrospective Studies
dc.subjectRisk Factors
dc.subjectSARS-CoV-2
dc.subjectUnited Kingdom
dc.subjectWorld Health Organization
dc.titleAcute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study.
dc.typeArticle
dc.date.updated2022-04-28T10:01:36Z
prism.endingPage284
prism.issueIdentifier2
prism.publicationDate2022
prism.publicationNameNephrol Dial Transplant
prism.startingPage271
prism.volume37
dc.identifier.doi10.17863/CAM.84013
rioxxterms.versionofrecord10.1093/ndt/gfab303
rioxxterms.versionVoR
dc.contributor.orcidSullivan, Michael K [0000-0002-3800-2330]
dc.contributor.orcidLees, Jennifer S [0000-0001-6331-0178]
dc.contributor.orcidSemple, Malcolm G [0000-0001-9700-0418]
dc.contributor.orcidHo, Antonia [0000-0003-1465-3785]
dc.contributor.orcidMark, Patrick B [0000-0003-3387-2123]
dc.identifier.eissn1460-2385
rioxxterms.typeJournal Article/Review
cam.issuedOnline2021-10-18
cam.depositDate2022-04-28
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International